[6] Catlin oversaw the testing for performance-enhancing drugs at the three most recent Olympics that were held in the United States, starting with the 1984 Summer Games in Los Angeles.
[12][13] In 2002 at the Winter Olympics in Salt Lake City, Catlin reported darbepoetin alfa, a form of the blood booster EPO (erythropoietin), for the first time in sports.
It was founded in 2005 to bolster efforts to uncover new drugs that are being used illegally by competitors, and to develop accurate tests in order to easily detect them in athletes.
[19][20] In addition, Catlin led both of the companies Anti-Doping Sciences Institute (ADSI) and Banned Substances Control Group (BSCG).
[21][22] In 2006, Catlin received a request from The Washington Post to analyze a dietary supplement created by Patrick Arnold, which he identified the active ingredient as methylhexaneamine.
[23] In 2009, Catlin and his team at Anti-Doping Research developed an equine test for the potent blood-boosting drug Mircera, also known as Continuous erythropoietin receptor activator.
[24] In a peer-reviewed article published in the August 2009 issue of the science journal Comparative Exercise Physiology, Catlin, along with colleagues at ADR, reported to have developed an equine test for the powerful blood-boosting drug CERA.